Abiopharma

🔍 Carter Kevin A. (Director)

Company: Quipt Home Medical Corp. (QIPT)

Report Date: 2026-03-16

Detailed Transactions and Holdings:

• Sold 201,160 shares of Common Shares at $3.65 per share (Direct)
  Date: 2026-03-16 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 5,625 shares of Stock Option (Right to Buy) at $6.27 per share (Derivative)
  Date: 2026-03-16 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F3, F3

Footnotes:

• F1: On March 16, 2026, 1567208 B.C. LTD, a company existing under the laws of British Columbia ("B.C. Purchaser"), and REM Aggregator, LLC, a Delaware limited liability company (individually, "REM Aggregator", and collectively with B.C. Purchaser ("Purchaser" or "Purchasers") acquired all of the issued and outstanding common shares (the "Shares") of Issuer under a plan of arrangement (the "Arrangement Agreement") pursuant to the Business Corporations Act (British Columbia) (the "BCBCA"). At the Effective Time (the "Effective Time") of the Arrangement Agreement each Share, other than any Shares held by shareholders who properly exercised dissent rights under the BCBCA ("Dissenting Shareholders"), were deemed to be transferred to Purchaser in consideration for the right to receive a cash payment from the Purchaser in the amount equal to US$3.65, without interest.
• F2: Pursuant to a forfeiture agreement entered into by Issuer and Mr. Carter, 76,732 restricted share units ("RSUs") were forfeited immediately prior to the Effective Time and terminated in connection with the Arrangement Agreement. Each RSU is the economic equivalent of one Share.
• F3: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option exercisable to acquire one or more Shares from the Issuer (an "Option"), outstanding immediately prior to the Effective Time (whether vested or unvested) were deemed to be unconditionally vested and exercisable and will, without any further action by or on behalf of a holder of the Option, deemed to be surrendered and transferred by such holder to the Issuer in consideration for the right to receive a cash payment from the Issuer in an amount equal to the excess, if any, of US$3.65 over the exercise price of such option, less any amounts the Issuer is required to withhold for taxes, without interest. Any option for which the exercise price is equal to or greater than US$3.65 will be cancelled for no consideration.